SCHEMBL5654887

SCHEMBL5654887

CCOc1ccccc1NC(=O)OCCCN1CCN(c2ccccc2OC)CC1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 6/20 0.66
ADRA1D P25100 5/20 0.66
ADRA1B P35368 5/20 0.66
DRD2 P14416 4/20 0.61
KDM4E B2RXH2 1/20 0.59
ALDH1A1 P00352 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
HTR1A P08908 3/20 0.58
HTR7 P34969 2/20 0.58
MAPK1 P28482 1/20 0.57
DRD3 P35462 3/20 0.57
ADRA2A P08913 1/20 0.57
DRD1 P21728 1/20 0.57
DRD4 P21917 1/20 0.57
DRD5 P21918 1/20 0.57
HTR2A P28223 1/20 0.57
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5656677 0.94 ADRA1D (0.60) ADRA1AADRA1DADRA1BDRD2KDM4E
SCHEMBL5655841 0.93 ADRA1A (0.71) ADRA1AADRA1DADRA1BDRD2KDM4E
SCHEMBL5657076 0.90 ADRA1D (0.53) ADRA1AADRA1DADRA1BDRD2HTR7
SCHEMBL5655907 0.90 ADRA1D (0.53) ADRA1AADRA1DADRA1BDRD2KDM4E
SCHEMBL5656119 0.89 PKM (0.61) ADRA1AADRA1DADRA1BALDH1A1MAPK1
SCHEMBL5656389 0.86 ADRA1D (0.65) ADRA1AADRA1DADRA1BDRD2HTR1A
SCHEMBL5654727 0.86 ADRA1D (0.62) ADRA1AADRA1DADRA1BDRD2HTR1A
SCHEMBL5655927 0.86 ADRA1A (0.62) ADRA1AADRA1DADRA1BDRD2ALDH1A1
SCHEMBL5655895 0.85 MEN1 (0.57) ADRA1AADRA1DADRA1BDRD2KDM4E
SCHEMBL5657183 0.85 DRD2 (0.55) ADRA1AADRA1DADRA1BDRD2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-20040058933-A1 Aryl carbamate derivatives, preperation and use thereof CEREP (FR) 2004-03-25 US disclosed
EP-1362041-A1 ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF Cerep (FR) 2003-11-19 EP disclosed
WO-2002068399-A1 ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF CEREP (FR) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058933-A1 Aryl carbamate derivatives, preperation and use thereof HTR4, HTR5A, HTR3C ADRA1A 294/4885ADRA1D 265/4885ADRA1B 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.